Lung cancer is the world’s deadliest cancer, yet fewer than 16% of high-risk individuals1 undergo annual screenings with low-dose CT scans (LDCTs).
ProVue Lung is a novel, blood-based Laboratory Developed Test (LDT) designed to improve lung cancer detection at its earliest and most treatable stages.
Philip Ma, CEO & Founder, PrognomiQ
Identifies many lung cancers, including at Stage I, when treatment is most effective.
Convenient blood draw reduces existing barriers to screening.
Designed for high-risk adults aged 50+ with a 20+ pack-year smoking history.
ProVue Lung is a proteomics test which was developed through PrognomiQ’s proprietary multi-omics platform to uncover unique molecular signatures of disease. This approach enables identification of disease at its earliest stages with high sensitivity.
Low-dose CT (LDCT) remains the recommended standard for lung cancer screening, yet adherence remains below 16% among eligible patients.1
ProVue Lung complements LDCT by providing an accessible and scalable tool to help increase screening participation.
An ELEVATED result indicates a higher risk for lung cancer than baseline for adults eligible for lung cancer screening.
An ELEVATED result does not definitively indicate that the the individual has lung cancer.
A NOT ELEVATED result indicates that an individual does not have a higher risk for lung cancer than baseline for adults eligible for lung cancer screening.
A NOT ELEVATED result does not guarantee absence of cancer or potential development of cancer in the future.
ProVue Lung was validated in multiple prospective, case-control studies, including in a separate independent cohort to assess Stage I sensitivity performance 2
NPV
Sensitivity for all-stages of lung cancer
Specificity
Sensitivity for stage I lung cancer
Phone: (650) 750-2450
Email: [email protected]
Indications for Use
ProVue Lung is intended as an adjunct assessment tool for adults deemed at high risk of lung cancer and consistent with lung cancer screening guidelines by USPSTF3, ACS4, and/or NCCN5.
Laboratory Information
The ProVue Lung test is a laboratory developed test (LDT). This test was developed by PrognomiQ. It has not been cleared nor approved by the US Food and Drug Association (FDA). The laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical tests. The test is used for clinical purposes. It should not be regarded as investigational or for research.
We are proud to be a CLIA-certified and CAP-accredited laboratory
References: 1. American Lung Association. Lung cancer key findings. Accessed November 13, 2024. https://www.lung.org/research/state-of-lung-cancer/key-findings 2. Unpublished data on file; manuscript under preparation 3. U. S. Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117 4. Wolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81. doi:10.3322/caac.21811 5. NCCN Guidelines® Insights: lung cancer screening, version 1.2026.
